Kalbe Farma Tbk EBIT

Kalbe Farma Tbk (PTKFY) currently reports a EBIT of $3.8T as of June 2026. That compares with $3.8T in the prior-year period — up 1.0% year over year. That is above the Healthcare sector average of $23B. Use the charts on this page to explore Kalbe Farma Tbk's EBIT history and peer comparisons.

Kalbe Farma Tbk's EBIT increased from $3.8T to $3.8T — a 1.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kalbe Farma Tbk's EBIT of $3.8T is higher than the Healthcare sector average of $23B. That is roughly 16374.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Kalbe Farma Tbk reported $3.8T in EBIT as of June 2026. That compares with $3.8T in the prior-year period — up 1.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $3.8T, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Kalbe Farma Tbk, and consider following PTKFY for alerts when major investors trade the stock.